Fit Investment Ideas

Pareto issued a note on Monday, that the FDA delay has no material impact on the Biovica value, and the sale off is unjustified. Redye research also came up with the same conclusion. The research is available for free on Biovica website. Full report is below: Redeye Research: Biovica: The submission of the updated applicationContinue reading “Biovica: Redeye Research joins Pareto in declaring the sell off as a nervous overreaction without and support in changing fundamentals”

The selling was due to the Biovica s press release stating that FDA is in delay due to the Corona Virus work overload. I enclose Pareto Minutes of the call with the management published minutes ago. The minutes indicate, that there is no justification for the sell off. The Biovica value does not change whetherContinue reading “Biovica sell off – Minutes of the call with the management”

SpareBank and Pareto have in their Top Pick portfolio for September jointly just one stock – Norske Skog. Two days ago I wrote here about Pareto strategic portfolio for September. I enclose below SpareBank Top Pick summary. As mentioned above, there is just one stock that is in both Top Pick portfolios – Norske Skog.Continue reading “SpareBank joins Pareto by adding Norske Skog into Top Pick Portfolio for September”

Sparebank believes the Norske Skog share price should be three times higher. NSKOG is my favorite restructuring play. NSKOG has four levers for share price growth: it is very cheap vs its peers – see below Sparebank: “if valued in line with peers, we argue that a fair price is closer to NOK 100” itsContinue reading “Sparebank on Norske Skog – Newsprint prices up 15%-20%. Share priced did not move, yet”

ABG Sundal Collier just issued their update on Biovica. I include the full report below. Very bullish There are two major points in the research: During the quarter, the company has interacted with theFDA and undergone a Submission Issue Request (SIR) process . This isa routine way for the FDA to resolve or clarify minorContinue reading “ABG Sundal on Biovica: “Closing on the finish Line””

Hofseth BioCare (Oslo: HBC) is a Norway-based company engaged in processing marine raw materials into products to enhance global health. Two years ago the company initiated its transformation. The road map to value creation is simple: In the first stage, move from low-margin animal feed towards high-margin finished products for pet and human-grade nutraceutical products available atContinue reading “Hofseth Biocare – the transformational deal with Garden of Life launched”

Pareto published their strategic portfolio for September for Norway and Sweden. Below is the summary. Pareto´s Norway Portfolio US indices ended close to new all-time highs in August. Our portfolio wasno different, returning 4.8% m/m – a 4.1 pp outperformance to OSEBXreturning 0.7% last month. We remain ahead of the index for the yearhaving returnedContinue reading “Pareto portfolio for September”

I had a privilege to speak to Quantafuel management for one hour after the webcast yesterday. The information was quite reassuring. Below is my summary of the interactive meeting. How certain are we that the modifications in Q4 would be sufficient The company has been testing and resolving issues during the last months. Many issuesContinue reading “Quantafuel – minutes of my meeting with QFUEL management”

Last year brought too many IPOs. As a result many good companies underperformed and this created an attractive opportunity. I like and I am long the below two IPOs from last year that are still trading below their IPO prices. Both reported today. I copy the summary of the Fearnley research on those. Both hadContinue reading “MPCES and HAV – Norway Green stocks beating expectations”